DEVELOPMENT OF DRUGS FOR SCHIZOPHRENIA AND DEMENTIA

精神分裂症和痴呆症药物的开发

• 批准号: 2537537
• 负责人: KURT R. BRUNDEN
• 金额: $ 9.75万
• 依托单位: GLIATECH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-05 至 1999-03-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2537537
• 关键词: NMDA receptors; cell line; dementia; dopamine transporter; drug design /synthesis /production; drug screening /evaluation; glycine; laboratory rat; mental disorder chemotherapy; molecular cloning; neurotransmitter transport; schizophrenia; serotonin transporter; transfection

The glutamate/glycine NMDA receptor has been implicated in a variety of central nervous system disorders and pathological conditions. In particular, NMDA receptor hypofunction appears to contribute significantly to schizophrenia and cognitive deficits. In the following application, a research program is described that is aimed at identifying novel drug candidates, for potentiating NMDA receptor activity. We have discovered prototype compounds, and further assay development and compound screening is proposed in this Phase I application. Novel molecules, which increase NMDA receptor function, have considerable commercial potential for the treatment of schizophrenia and of dementias such as Alzheimer's disease. PROPOSED COMMERCIAL APPLICATIONS: Compounds identified through the studies outlined in this proposal will have the potential for the treatment of schizophrenia and dementias such as Alzheimer's disease.

谷氨酸盐/甘氨酸NMDA受体与多种 中枢神经系统疾病和病理状况。在 特别是，NMDA受体功能减退似乎显着有助于 精神分裂症和认知缺陷在下面的应用程序中， 描述了一项旨在鉴定新药的研究计划 候选人，用于增强NMDA受体活性。我们已经发现 原型化合物，以及进一步的测定开发和化合物筛选 在第一阶段申请中提出。新型分子， NMDA受体功能，具有相当大的商业潜力， 治疗精神分裂症和痴呆症如阿尔茨海默病。 拟议的商业应用： 通过本提案中概述的研究确定的化合物将 具有治疗精神分裂症和痴呆症的潜力， 老年痴呆症